Press Releases

-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc.

EMERYVILLE, Calif. , April 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced it will make six data presentations at the 70 th  Annual Meeting of the American Academy of Neurology (AAN ) on April 21-27, 2018 in Los Angeles, California .

EMERYVILLE, Calif. , April 03, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial of ADS-5102 (amantadine) extended release capsules in multiple sclerosis (MS) patients with walking

-- Pooled analyses of GOCOVRI Phase 3 data published in CNS Drugs -- EMERYVILLE, Calif. , March 15, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules for the treatment of dyskinesia in

EMERYVILLE, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences: Gregory T. Went , Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled

EMERYVILLE, Calif. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31 , 2017.  “I’m very proud of the accomplishments made by the Adamas team in 2017,

EMERYVILLE, Calif. , Feb. 19, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced today that it has learned that Osmotica Pharmaceuticals LLC and Vertical Pharmaceuticals LCC (Osmotica) filed an action in Delaware federal court on February 16, 2018 requesting a declaratory

EMERYVILLE, Calif. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018 after market close. Subsequently, Adamas’ management team will host a

EMERYVILLE, Calif. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 42,250 shares of the company’s common stock, at a

EMERYVILLE, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate release (IR) who were still experiencing dyskinesia and enrolled into EASE LID 2, the long-term,